PMID- 34610830
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20221207
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 20
IP  - 1
DP  - 2021 Oct 5
TI  - Atherogenic index of plasma is associated with major adverse cardiovascular 
      events in patients with type 2 diabetes mellitus.
PG  - 201
LID - 10.1186/s12933-021-01393-5 [doi]
LID - 201
AB  - BACKGROUND: Previous studies reported the prognostic value of the atherogenic 
      index of plasma (AIP) in the course of atherosclerosis and other cardiovascular 
      diseases (CVDs). Still, the predictive utility of the AIP is unknown among 
      patients with type 2 diabetes mellitus (T2DM). METHODS: This was a secondary 
      analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, 
      which randomized 10,251 patients with long-lasting T2DM. ROC curve analysis was 
      used to determine an optimal threshold for AIP, and the study population was 
      divided into high and low AIP groups. Univariable and multivariable Cox 
      proportional hazards regression analyses were used to determine the association 
      between AIP and primary (major adverse cardiovascular events [MACEs], including 
      nonfatal myocardial infarction, nonfatal stroke, and/or death from cardiovascular 
      causes) and secondary outcomes (all-cause mortality). Stratified analyses were 
      performed to control for the confounding factors. RESULTS: AIP was an independent 
      risk factor for the prognosis of T2DM (HR = 1.309; 95% CI 1.084-1.581; 
      P = 0.005). The threshold for AIP was determined to be 0.34 in the study 
      population. After adjustments for confounding factors, multivariable analysis 
      showed that AIP was associated with the risk of MACEs (Model 1: HR = 1.333, 95% 
      CI 1.205-1.474, P < 0.001; Model 2: HR = 1.171, 95% CI 1.030-1.333, P = 0.016; 
      Model 3: HR = 1.194, 95% CI 1.049-1.360, P = 0.007), all-cause mortality (Model 
      1: HR = 1.184, 95% CI 1.077-1.303, P < 0.001), cardiovascular death (Model 1: 
      HR = 1.422, 95% CI 1.201-1.683, P < 0.001; Model 3: HR = 1.264, 95% CI 
      1.015-1.573, P = 0.036), and nonfatal myocardial infarction (Model 1: HR = 1.447, 
      95% CI 1.255-1.669, P < 0.001; Model 2: HR = 1.252, 95% CI 1.045-1.499, 
      P = 0.015; Model 3: HR = 1.284, 95% CI 1.071-1.539, P = 0.007). Subgroup 
      stratified analyses showed that AIP might interact with sex, a classical risk 
      factor of cardiovascular events. CONCLUSIONS: This study showed that AIP might be 
      a strong biomarker that could be used to predict the risk of cardiovascular 
      events in patients with T2DM. TRIAL REGISTRATION: URL: 
      http://www.clinicaltrials.gov . Unique identifier: NCT00000620.
CI  - (c) 2021. The Author(s).
FAU - Fu, Liyao
AU  - Fu L
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Sun, Jiaxing
AU  - Sun J
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Zhu, Zhaowei
AU  - Zhu Z
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Xing, Zhenhua
AU  - Xing Z
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Zhou, Shenghua
AU  - Zhou S
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Blood Transfusion, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Tai, Shi
AU  - Tai S
AUID- ORCID: 0000-0002-5802-2910
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, No. 139, Middle Renmin Road, Changsha, 410011, Hunan, People's 
      Republic of China. taishi2017@csu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT00000620
GR  - 81801394/National Natural Science Foundation of China/
GR  - 2019JJ50878/Natural Science Foundation of Hunan Province/
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20211005
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atherosclerosis/*blood/diagnosis/mortality
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - Cholesterol, HDL/*blood
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/mortality
MH  - Dyslipidemias/*blood/diagnosis/mortality
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - North America
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Sex Factors
MH  - Time Factors
MH  - Triglycerides/*blood
PMC - PMC8493717
OTO - NOTNLM
OT  - Atherogenic index of plasma
OT  - Atherosclerosis
OT  - Cardiovascular disease
OT  - Major adverse cardiovascular events
OT  - Prognosis
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/10/07 06:00
MHDA- 2022/02/01 06:00
PMCR- 2021/10/05
CRDT- 2021/10/06 05:32
PHST- 2021/08/19 00:00 [received]
PHST- 2021/09/28 00:00 [accepted]
PHST- 2021/10/06 05:32 [entrez]
PHST- 2021/10/07 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/10/05 00:00 [pmc-release]
AID - 10.1186/s12933-021-01393-5 [pii]
AID - 1393 [pii]
AID - 10.1186/s12933-021-01393-5 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2021 Oct 5;20(1):201. doi: 10.1186/s12933-021-01393-5.